Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed/Refractory, High Risk Hematologic Malignancies”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Study completedNCT00538850
What this trial is testing

Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain

Who this might be right for
Cancer
INSYS Therapeutics Inc 130
Testing effectiveness (Phase 2)Study completedNCT00683046
What this trial is testing

T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies

Who this might be right for
Acute Myelogenous LeukemiaLymphoid LeukemiaChronic Myelogenous Leukemia+6 more
University of Chicago 204
Testing effectiveness (Phase 2)Study completedNCT00017342
What this trial is testing

Bryostatin 1 and Cytarabine in Treating Patients With Relapsed Acute Myelogenous Leukemia

Who this might be right for
Leukemia
Virginia Commonwealth University
Testing effectiveness (Phase 2)Ended earlyNCT03104270
What this trial is testing

Combination Study for High Risk Multiple Myeloma Patients

Who this might be right for
Multiple Myeloma
Oncotherapeutics 13
Testing effectiveness (Phase 2)Looking for participantsNCT05010122
What this trial is testing

ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Who this might be right for
Acute Myeloid LeukemiaMyelodysplastic SyndromeRecurrent Acute Myeloid Leukemia+1 more
M.D. Anderson Cancer Center 42
Early research (Phase 1)Ended earlyNCT02848001
What this trial is testing

A Dose-finding Study of CC-90009 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Myelodysplastic Syndromes

Who this might be right for
Leukemia, Myeloid, AcuteMyelodysplastic Syndromes
Celgene 101
Early research (Phase 1)Looking for participantsNCT06994676
What this trial is testing

CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias

Who this might be right for
High-risk Myelodysplastic SyndromeChronic Myelomonocytic Leukemia (CMML)AML - Acute Myeloid Leukemia+1 more
Crossbow Therapeutics, Inc. 72
Testing effectiveness (Phase 2)Study completedNCT00809276
What this trial is testing

Allo BMT Using Matched Related/Unrelated Donors With FluBu and HiCY

Who this might be right for
LymphomaMultiple MyelomaLeukemia+1 more
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 92
Testing effectiveness (Phase 2)Ended earlyNCT06268574
What this trial is testing

Safety and Efficacy of RVU120 for Treatment of Relapsed/Refractory AML

Who this might be right for
Acute Myeloid Leukemia (AML)High-risk Myelodysplastic Syndrome
Ryvu Therapeutics SA 62
Large-scale testing (Phase 3)UnknownNCT00747877
What this trial is testing

High-Dose Melphalan and a Second Stem Cell Transplant or Low-Dose Cyclophosphamide in Treating Patients With Relapsed Multiple Myeloma After Chemotherapy

Who this might be right for
Multiple Myeloma and Plasma Cell Neoplasm
Leeds Cancer Centre at St. James's University Hospital 460
Testing effectiveness (Phase 2)UnknownNCT05809167
What this trial is testing

Venetoclax+Azacytidine+Modified BUCY Conditioning Regimen for Acute Lymphoblastic Leukemia Undergoing Allo-HSCT

Who this might be right for
Allogeneic Hematopoietic Stem Cell TransplantationAcute Lymphoblastic Leukemia
The First Affiliated Hospital of Soochow University 55
Large-scale testing (Phase 3)Study completedNCT00048230
What this trial is testing

PS-341 (VELCADE™) Versus High-Dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Millennium Pharmaceuticals, Inc. 620
Testing effectiveness (Phase 2)Ended earlyNCT00792506
What this trial is testing

Phase II Clinical Trial of ITF2357 In Patients With Relapsed/Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Italfarmaco 1
Testing effectiveness (Phase 2)Study completedNCT00002833
What this trial is testing

Peripheral Stem Cell Transplantation Plus Filgrastim in Treating Patients With Acute or Chronic Myelogenous Leukemia

Who this might be right for
Graft Versus Host DiseaseLeukemiaMyelodysplastic Syndromes
M.D. Anderson Cancer Center 53
Early research (Phase 1)Study completedNCT04901416
What this trial is testing

Safety and Efficacy of Allogeneic NK Cell Infusions in Patients With Relapsed/Refractory AML and High Risk MDS

Who this might be right for
AML, Adult RecurrentMDS
Coeptis Therapeutics 8
Early research (Phase 1)Study completedNCT00401739
What this trial is testing

Safety, Tolerability and Pharmacokinetics of CSL360 in the Treatment of Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid Leukemia (AML)
CSL Limited 40
Early research (Phase 1)Looking for participantsNCT06146257
What this trial is testing

GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher Risk Myelodysplastic Syndromes

Who this might be right for
Acute Myeloid LeukemiaMyelodysplastic Syndromes
GluBio Therapeutics Inc. 48
Early research (Phase 1)Looking for participantsNCT02508038
What this trial is testing

Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors

Who this might be right for
Acute Myeloid LeukemiaAcute Lymphoblastic LeukemiaHodgkin Lymphoma+8 more
University of Wisconsin, Madison 22
Testing effectiveness (Phase 2)UnknownNCT04749355
What this trial is testing

Phase 2, Open-Label, Single Arm Study, With BST-236 in Adults With R/R AML or Higher-Risk MDS

Who this might be right for
AML, AdultMDSRelapse/Recurrence+1 more
BioSight Ltd. 40
Testing effectiveness (Phase 2)Looking for participantsNCT07591649
What this trial is testing

Adapt NK for High Risk Myeloid Diseases as Bridge to Allo HSCT

Who this might be right for
Relapsed Adult AMLRefractory AMLAcute Myelogenous Leukemia
Masonic Cancer Center, University of Minnesota 18
Next Page